Trending Stock News

Genomic Health, Inc. (GHDX) Reaches $33.95 After 8.00% Down Move; Taylor Wimpey plc (LON:TW) Had 12 Bulls

The stock of Genomic Health, Inc. (NASDAQ:GHDX) is a huge mover today! The stock decreased 2.67% or $0.93 during the last trading session, reaching $33.95. About 100,558 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has risen 23.46% since January 18, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.The move comes after 8 months negative chart setup for the $1.18 billion company. It was reported on Jan, 18 by Barchart.com. We have $31.23 PT which if reached, will make NASDAQ:GHDX worth $94.48 million less.

Among 21 analysts covering Taylor Wimpey PLC (LON:TW), 12 have Buy rating, 1 Sell and 8 Hold. Therefore 57% are positive. Taylor Wimpey PLC had 226 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, September 16 by Deutsche Bank. Beaufort Securities maintained the shares of TW in report on Thursday, January 12 with “Buy” rating. The firm earned “Buy” rating on Tuesday, April 19 by Deutsche Bank. The firm has “Buy” rating by Deutsche Bank given on Monday, March 7. Peel Hunt upgraded the stock to “Buy” rating in Monday, January 9 report. Numis Securities maintained Taylor Wimpey plc (LON:TW) rating on Tuesday, March 1. Numis Securities has “Add” rating and GBX 205 target. Deutsche Bank maintained it with “Buy” rating and GBX 247 target in Friday, April 29 report. Deutsche Bank maintained Taylor Wimpey plc (LON:TW) on Monday, June 20 with “Buy” rating. The firm earned “Add” rating on Monday, November 16 by Numis Securities. The rating was maintained by Canaccord Genuity on Tuesday, October 4 with “Buy”. See Taylor Wimpey plc (LON:TW) latest ratings:

10/01/2018 Broker: Numis Securities Rating: Hold New Target: GBX 221.00 Downgrade
10/01/2018 Broker: Shore Capital Rating: Hold Maintain
10/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 210.00 New Target: GBX 210.00 Downgrade
10/01/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 200.00 New Target: GBX 200.00 Maintain
08/01/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 220.00 New Target: GBX 220.00 Maintain
08/01/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 200.00 New Target: GBX 200.00 Maintain
05/01/2018 Broker: Peel Hunt Rating: Add Old Target: GBX 210.00 New Target: GBX 210.00 Maintain
03/01/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 181.00 New Target: GBX 200.00 Maintain
18/12/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 246.00 New Target: GBX 246.00 Maintain
14/12/2017 Broker: JP Morgan Rating: Overweight Old Target: GBX 210.00 New Target: GBX 220.00 Maintain

It closed at GBX 196.65 lastly. It is down 0.00% since January 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Taylor Wimpey plc operates as a homebuilding firm in the United Kingdom and Spain. The company has market cap of 6.42 billion GBP. It manufactures various homes, such as one- and two-bedroom apartments, and five-bedroom detached houses. It has a 11.99 P/E ratio.

Investors sentiment increased to 2.32 in 2017 Q3. Its up 0.66, from 1.66 in 2017Q2. It is positive, as 6 investors sold Genomic Health, Inc. shares while 25 reduced holdings. 21 funds opened positions while 51 raised stakes. 30.86 million shares or 1.02% more from 30.55 million shares in 2017Q2 were reported. Legal General Group Public Ltd Co reported 7,332 shares. Jane Street Grp Incorporated Ltd Liability Com reported 0% stake. The New York-based Goldman Sachs Gp has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). State Street Corp has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Hutchin Hill Cap L P owns 8,900 shares or 0.01% of their US portfolio. Alliancebernstein L P owns 75,155 shares for 0% of their portfolio. Spark Investment Lc has invested 0.23% in Genomic Health, Inc. (NASDAQ:GHDX). First Quadrant Lp Ca invested in 208 shares or 0% of the stock. Sei Invs Commerce reported 113 shares or 0% of all its holdings. Baker Bros Advsr Ltd Partnership owns 13.78M shares. Blackrock holds 0% or 2.20 million shares in its portfolio. Vanguard Group Inc Inc has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX). Macquarie Grp Limited accumulated 38,000 shares or 0% of the stock. Nordea Investment Ab owns 0.01% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 68,812 shares. Retail Bank Of America De has 138,634 shares.

Among 11 analysts covering Genomic Health (NASDAQ:GHDX), 2 have Buy rating, 3 Sell and 6 Hold. Therefore 18% are positive. Genomic Health had 31 analyst reports since August 5, 2015 according to SRatingsIntel. The company was upgraded on Monday, November 23 by UBS. The rating was maintained by Canaccord Genuity on Wednesday, November 15 with “Buy”. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, January 4. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Outperform” rating by Raymond James on Wednesday, November 4. The rating was downgraded by JP Morgan on Wednesday, December 13 to “Underweight”. On Thursday, November 19 the stock rating was upgraded by Cowen & Co to “Outperform”. On Thursday, August 6 the stock rating was downgraded by Zacks to “Hold”. William Blair downgraded the stock to “Hold” rating in Wednesday, December 20 report. The rating was maintained by Jefferies with “Hold” on Friday, October 20. Barclays Capital initiated Genomic Health, Inc. (NASDAQ:GHDX) rating on Wednesday, September 2. Barclays Capital has “Underweight” rating and $25.0 target.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company has market cap of $1.18 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. It currently has negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on February, 13. They expect $0.09 earnings per share, up 125.00% or $0.05 from last year’s $0.04 per share. GHDX’s profit will be $3.13M for 94.31 P/E if the $0.09 EPS becomes a reality. After $0.03 actual earnings per share reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts 200.00% EPS growth.

Since August 8, 2017, it had 0 buys, and 12 insider sales for $2.98 million activity. Febbo Phillip G. had sold 5,334 shares worth $197,298 on Tuesday, December 19. The insider Popovits Kimberly J sold 5,000 shares worth $154,989. Cole G Bradley sold $159,637 worth of stock or 5,000 shares. 8,000 shares valued at $244,724 were sold by Vaughn James J on Tuesday, August 8. $699,000 worth of Genomic Health, Inc. (NASDAQ:GHDX) shares were sold by Leber Laura.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *